SpinaFX Medical Inc. is pleased to announce the appointment of John Soloninka as Chief Executive Officer.
John joined SpinaFX in 2021, as the first executive hire, taking progressive roles as COO, CTO and CSO. His leadership and expertise were critical in establishing the company with ISO 13485/MDSAP certification and achieving major regulatory milestones including FDA Breakthrough Device Designation and FDA IDE Approval, Health Canada SAP, and most recently CE Mark MDR.
Over a thirty-year career in health technology, John has co-founded and financed multiple companies and funds, raising over $50M in capital for seven start-ups; as fund CEO, led financing for thirty-six early-stage medtech ventures; and as Board member of organizations in oncology, neuroscience and clinical trials, secured $425M in public-private research funding.
Together with the Board, John’s immediate priorities will be leading financing, SpinaFX’s pivotal clinical trial in the US, and commercialization of the newly approved Triojection® device in the EU.